Hepatitis

WHO Global Partners' Meeting on Hepatitis Elimination - February 2019

WHO urges shift from advocacy to action on hepatitis elimination

26 February 2019 – WHO will host a global meeting in Geneva, Switzerland, on 27–28 February with the aim of leveraging a new partnership push to eliminate hepatitis. The meeting will bring together countries and partner organizations to jointly advocate for accelerated action and to mobilize country partnerships to achieve impact where it is most needed. Hepatitis elimination, including scale-up of access to hepatitis C curative treatment, is recognized as a “flagship” initiative by WHO Director-General Dr Tedros. #Heppartners2019

New consolidated guidelines on hepatitis strategic information

New consolidated guidelines on hepatitis strategic information

22 February 2019 - The new Consolidated strategic information guidelines for viral hepatitis summarize and simplify the overall approach proposed by WHO to collect, analyse, disseminate and use strategic information on viral hepatitis at local, subnational, national and international levels. It describes the use of strategic information at various stages of the response in the context of strengthening broader health information systems. Strategic information can be defined as data collected at all service delivery and administrative levels to inform policy and programme decisions.

Mother holding child in her arms.

HIV and Hepatitis Update - December 2018

Director's message - As 2018 is coming to a close, I would like to thank you, on behalf of WHO’s dedicated HIV and Hepatitis team, for your continued support, your inspiration, and the active collaboration during this year.

Best wishes for a healthy and happy new year 2019!

WHO
Stopping endemic hepatitis B and D in Ayacucho, Peru

Stopping endemic hepatitis B and D in Ayacucho, Peru

21 December 2018 – Child vaccination programmes are beating endemic hepatitis B in Ayacucho and a new elimination plan now seeks to address the remaining challenges around how to support people who are already chronically infected. In the coming year, testing and treatment will be expanded to other sites in Ayacucho. The elimination plan includes birth dose vaccination of newborns; prenatal testing and interventions to prevent transmission from pregnant women with HBV to their infants; and diagnosis, treatment and follow-up for chronic HBV carriers.

PAHO
Key stakeholders meet in Islamabad, Pakistan to develop a course of action for hepatitis elimination in the country.

Pakistan’s investment in hepatitis may see return within years

21 December 2018 – Better use of strategic information in Pakistan is driving progress towards hepatitis elimination. An estimated 8 million people are affected by hepatitis C virus (HCV) in Pakistan (around 5% of the population), making its epidemic the second largest in the world. The good news is that HCV can be cured in more than 90% of cases using direct-acting antiviral drugs (DAAs). However, low-, middle- and high-income countries are battling to get treatment to people who are chronically infected due to drug procurement and cost challenges.

WHO
Initiating Hepatitis C treatment in Afghanistan

Initiating hepatitis C treatment in Afghanistan

5 December 2018 – Afghanistan has substantial hepatitis prevalence, particularly among injecting drug users, men and women with high risk behaviours, and refugees migrating from the neighbouring countries of Islamic Republic of Iran and Pakistan. From 2011 to June 2018, a total of 18 089 positive tests were reported. Between 2018–2020, it is planned to treat 20 000 affected people. WHO is providing technical support to the Ministry of Public Health to train clinicians on hepatitis C management in order to initiate treatment in the public health sector.

WHO
Hepatitis patients, Pakistan

Important new agreement on hepatitis C treatment signed

14 November 2018 – The World Health Organization (WHO) commends the new royalty-free licence agreement signed today between the Medicines Patent Pool (MPP) and AbbVie for for glecaprevir/pibrentasvir (G/P) – WHO’s recommended hepatitis C treatment (HCV). The licence will enable manufacturers to develop and sell generic medicines containing G/P in 99 low- and middle-income countries at affordable prices, enabling access to and treatment scale-up with the most effective pan-genotypic regimens.

PKLI

 


About hepatitis

Fact sheets on hepatitis


World Hepatitis Day

Previous campaigns

Elimination of hepatitis by 2030

Global hepatitis report, 2017 - infographic: Towards elimination of hepatitis by 2030

 


Stay connected

Global Hepatitis Programme